TYK2 and psoriasis: Overall, these findings suggested that, like apremilast, a PDE4 inhibitor that has been widely used as a systemic drug for psoriasis since its approval in 2014, TYK2 inhibitors also have the potential to serve as a type of novel medications for the systemic treatment of psoriasis, holding substantial promise in filling the existing treatment gaps.